Modulation of agonist binding to recombinant human alpha2-adrenoceptors by sodium ions.
Agonist binding to alpha2-adrenoceptors is modulated by a number of factors such as Mg2+ and Na+ ions and by experimental manipulations which interfere with receptor-G-protein-coupling such as pertussis toxin pre-treatment or the presence of guanine nucleotides. Agonist binding assays may therefore offer an opportunity to make inferences, albeit indirect, about receptor states or conformations and about the molecular nature of the processes involved in receptor activation. We have investigated possible differences in the effects of Na+ ions on the binding of agonists to the three human alpha2-adrenoceptor subtypes, alpha2A, alpha2B and alpha2C, recombinantly expressed in S115 mouse mammary tumour cells. NaCl (40 mM) influenced the apparent affinity of a panel of alpha2-adrenoceptor ligands in a complex compound- and subtype-dependent manner. Sodium ions affected both high- and low-affinity conformations of the receptors, as defined by co-incubation with 10 microM 5'-guanylylimidodiphosphate (Gpp(NH)p). The effects of NaCl and Gpp(NH)p on agonist binding were additive indicating different modes of action for the two allosteric modulators. Thus, quite marked differences between closely related receptor subtypes were noted in the molecular details of agonist-receptor interactions and in the integration of allosteric modulation by Na+ ions. Possible explanations for the experimental findings are discussed within the theoretical framework of multi-state models, and a proposal is presented for a potential physiological role of the modulatory effect of Na+ ions, where intracellular Na+ concentrations would direct the activating influence of receptors to different G-proteins.
Pihlavisto
M
M
Department of Pharmacology and Clinical Pharmacology, University of Turku, MediCity, Tykistökatu 6 A, FIN-20520 Turku, Finland.
Sjöholm
B
B
Scheinin
M
M
Wurster
S
S
D000316:Adrenergic alpha-Agonists / Q000378:metabolism*; D000494:Allosteric Regulation; D000818:Animals; D001667:Binding, Competitive; D002414:Cations, Monovalent / Q000494:pharmacology; D006165:Guanylyl Imidodiphosphate / Q000494:pharmacology; D006801:Humans; D019329:Idazoxan / Q000031:analogs & derivatives / Q000378:metabolism; D015674:Mammary Neoplasms, Animal; D051379:Mice; D009638:Norepinephrine / Q000378:metabolism; D018341:Receptors, Adrenergic, alpha-2 / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D011994:Recombinant Proteins / Q000187:drug effects / Q000378:metabolism; D012964:Sodium / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
C547768:ADRA2A protein, human; C547771:ADRA2B protein, human; C547774:ADRA2C protein, human; C547769:Adra2a protein, mouse; C547772:Adra2b protein, mouse; C547775:Adra2c protein, mouse; D000316:Adrenergic alpha-Agonists; D002414:Cations, Monovalent; D018341:Receptors, Adrenergic, alpha-2; D011994:Recombinant Proteins; D006165:Guanylyl Imidodiphosphate; D012964:Sodium; C058525:2-methoxyidazoxan; D009638:Norepinephrine; D019329:Idazoxan